🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "major milestone" in the battle against increasingly resistant strains of the pathogen, according to health experts.

A Global Health Concern

The sexually transmitted infection are increasing worldwide, with estimates suggesting in excess of 82 million instances each year. Especially elevated rates are seen in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely development in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Medical experts are deeply concerned about the increase in antibiotic-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Secure Authorization

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in mid-December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers believe that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in close succession. This medication, which is also used to treat urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a unique collaborative effort for drug creation. The non-profit organisation GARDP partnered with the drug firm Innoviva to develop it.

“This milestone represents a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Data and Worldwide Availability

Based on results published in a prominent scientific publication, the new drug successfully treated the vast majority of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which involves an injection and a pill. The research involved nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the rights to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians directly involved have shared positive views. Access to a easy-to-administer therapy such as this is seen as a "game-changer" for gonorrhoea control. This is considered crucial to lessen the impact of the infection for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.